Background and Objectives: Mast cell disorders comprise a wide spectrum of syndromes caused by mast cells' degranulation with acute or chronic clinical manifestations. Materials and Methods: In this review article we reviewed the latest findings in scientific papers about mast cell disorders with a particular focus on mast cell activation syndrome and mastocytosis in pediatric age. Results: Patients with mast cell activation syndrome have a normal number of mast cells that are hyperreactive upon stimulation of various triggers. We tried to emphasize the diagnostic criteria, differential diagnosis, and therapeutic strategies. Another primary mast cell disorder is mastocytosis, a condition with a long-known disease, in which patients have an increased number of mast cells that accumulate in different regions of the body with different clinical evolution in pediatric age. Conclusions: Mast cell activation syndrome overlaps with different clinical entities. No consensus was found on biomarkers and no clearly resolutive treatment is available. Therefore, a more detailed knowledge of this syndrome is of fundamental importance for a correct diagnosis and effective therapy.
Background and Objectives:Mast cell disorders comprise a wide spectrum of syndromes caused by mast cells' degranulation with acute or chronic clinical manifestations. Materials and Methods: In this review article we reviewed the latest findings in scientific papers about mast cell disorders with a particular focus on mast cell activation syndrome and mastocytosis in pediatric age. Results:Patients with mast cell activation syndrome have a normal number of mast cells that are hyperreactive upon stimulation of various triggers. We tried to emphasize the diagnostic criteria, differential diagnosis, and therapeutic strategies. Another primary mast cell disorder is mastocytosis, a condition with a long-known disease, in which patients have an increased number of mast cells that accumulate in different regions of the body with different clinical evolution in pediatric age. Conclusions: Mast cell activation syndrome overlaps with different clinical entities. No consensus was found on biomarkers and no clearly resolutive treatment is available. Therefore, a more detailed knowledge of this syndrome is of fundamental importance for a correct diagnosis and effective therapy.
Authors: Lauren M Raymond; Tracy Funk; Rita M Braziel; Guang Fan; Ken Gatter; Marc Loriaux; Jennifer Dunlap; Philipp W Raess Journal: Br J Haematol Date: 2020-04-03 Impact factor: 6.998
Authors: P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett Journal: Leuk Res Date: 2001-07 Impact factor: 3.156
Authors: R Y Lin; L B Schwartz; A Curry; G R Pesola; R J Knight; H S Lee; L Bakalchuk; C Tenenbaum; R E Westfal Journal: J Allergy Clin Immunol Date: 2000-07 Impact factor: 10.793
Authors: B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma Journal: Proc Natl Acad Sci U S A Date: 1999-02-16 Impact factor: 11.205